Clinical Trial

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated May 31, 2025 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-08-24; most recent amendment 2025-05-26.
Trial Details
NCT Number NCT05518253
Lead Sponsor Weijia Fang, MD
Collaborators: Chongqing Precision Biotech Co., Ltd
Conditions Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer
Enrollment 30 participants
Start Date 2022-05-30
Primary Completion 2026-05-30 (estimated)
Study Completion 2027-05-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-31